Development of a Medication Monitoring System for an Integrated Multidisciplinary Program of Assertive Community Treatment (IMPACT) Team by Watkins, Sarah C. et al.
Volume 3 | Number 4 Article 99
2012
Development of a Medication Monitoring System
for an Integrated Multidisciplinary Program of
Assertive Community Treatment (IMPACT)
Team
Sarah C. Watkins
Bruce R. Winchester
Nancy C. Brahm
Nicole B. Washington
Follow this and additional works at: http://pubs.lib.umn.edu/innovations
INNOVATIONS in pharmacy is published by the University of Minnesota Libraries Publishing.
Recommended Citation
Watkins SC, Winchester BR, Brahm NC, Washington NB. Development of a Medication Monitoring System for an Integrated
Multidisciplinary Program of Assertive Community Treatment (IMPACT) Team. Inov Pharm. 2012;3(4): Article 99.
http://pubs.lib.umn.edu/innovations/vol3/iss4/10
Student Project PRACTICE-BASED RESEARCH 
 
http://z.umn.edu/INNOVATIONS                        2012, Vol. 3, No. 4, Article 99                          INNOVATIONS in pharmacy   1 
 
Development of a Medication Monitoring System for an Integrated Multidisciplinary 
Program of Assertive Community Treatment (IMPACT) Team 
Sarah C. Watkins*, PharmD Candidate
1
; Bruce R. Winchester*, PharmD Candidate
1
; Nancy C. Brahm, PharmD, MS, BCPP, CGP, 
Clinical Professor
1
; and Nicole B. Washington, DO, Assistant Professor
2
 
1
University of Oklahoma College of Pharmacy and 
2
Department of Psychiatry, School of Community Medicine, Tulsa, OK 
 
Key words: antidepressant, antipsychotic, assertive community treatment, medication management, monitoring 
 
Abstract 
Purpose: The primary goal was to improve medication management oversight for a severely mentally ill (SMI) community-based 
population by developing a medication monitoring system based on current guidelines to optimize pharmacotherapy and minimize 
potential medication-related adverse effects. The secondary goal was improvement in coordination of care between healthcare 
providers. Methods: Guidelines for medication used for psychiatric indications were reviewed. A database of medication for 
psychiatric indications with monitoring recommendation was developed. Results: Medication regimens for 68 members of the 
Integrated Multidisciplinary Program of Assertive Community Treatment (IMPACT) program qualified for review. Fourteen 
medications, carbamazepine, chlorpromazine, clozapine, fluphenazine and fluphenazine long-acting injections (LAI), haloperidol and 
haloperidol LAI, lithium, lurasidone, olanzapine, paliperidone and paliperidone LAI, perphenazine, quetiapine, risperidone and 
risperidone LAI, valproic acid/divalproex, and ziprasidone, were identified. In total, 111 medications are used on a monthly basis. 
Each member receives more than one medication qualifying for review. Additional monitoring parameters that were evaluated 
included changes in laboratory orders for members with insulin-dependent diabetes. Annual lipid panels were changed to every 6 
months, if applicable. Conclusions and Future Directions: This medication monitoring program was developed to help ensure IMPACT 
members receive the most effective care and minimize potential medication-related adverse effects. The secondary goal was to 
improve coordination of care. Medication monitoring will be added as a continuous quality assurance measure. Lab results will be 
reviewed at least monthly. The medication monitoring program will be evaluated annually.  
 
 
Introduction 
Originally called training in community living
1
, programs of 
assertive community treatment (PACT) provide an 
organizational structure for clearly defined service delivery to 
persons diagnosed with severe mental illnesses (SMI) residing 
in the community. The emphasis is on a team approach with a 
multidisciplinary group of mental health professionals 
providing care for those with a SMI working and residing in a 
community-based setting. PACT teams have a holistic service 
delivery approach providing assistance with finances, 
housing, medical services, and medication management. 
These services are needed to address the special needs of 
those with a SMI diagnosis. It has been reported that this 
population has an increased mortality risk of up to 25 years 
shorter compared to the general population.
2
 The primary 
health risk factor in this cohort, particularly those with a  
diagnosis of schizophrenia, is cardiovascular-related, with 
special emphasis on elevated lipids.
3,4
 The impact of lifestyle  
choices, such as diet and exercise, cognitive impairment as a  
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consequence of the SMI, and antipsychotic-mediated weight 
gain can all contribute. Additional variables are the choice of 
antipsychotic, body mass index at time of medication 
initiation, and duration of medication use.
5
  
 
Economic barriers pose another challenge. Medication 
adherence may be a problem.  Acquisition and storage are 
challenges in persons with unstable living arrangements, such 
as in shelters or homelessness.
6
 PACT teams also address 
these needs.  
 
We describe the development of a medication monitoring 
system to help ensure members enrolled in an integrated 
multidisciplinary program of assertive community treatment 
(IMPACT) in one institution are evaluated for potential 
medication-related adverse effects associated with 
medications used to treat psychiatric illnesses. The secondary 
goal was to improve coordination of care between the 
primary care providers (PCPs) and the IMPACT team.  
 
Overview of the Service 
The IMPACT team is a university-based service comprised of a 
psychiatrist, psychiatry resident, team leader (Licensed 
Clinical Social Worker), assistant team leader (Licensed 
Professional Counselor), two case managers, one recovery 
Student Project PRACTICE-BASED RESEARCH 
 
http://z.umn.edu/INNOVATIONS                        2012, Vol. 3, No. 4, Article 99                          INNOVATIONS in pharmacy   2 
 
support specialist, three nurses, an administrative assistant, 
and a clinical pharmacist. Member enrollment is limited to 75 
persons. Criteria for enrollment are based on the Diagnostic 
and Statistical Manual of Mental Disorders, 4
th
 edition, text 
revision (DSM-IV-TR)
7
 for adults with a primary diagnosis of 
schizophrenia, bipolar disorder, or other psychotic disorders. 
Admission criteria are listed in Appendix 1.  
 
IMPACT members are seen for medication management on 
an individual basis. Depending on the member’s ability to 
function in the community setting and resources available, 
such as housing, an IMPACT provider may visit from once 
daily to no less than once weekly. Each member is seen in at 
least monthly in clinic by the psychiatrist, psychiatry resident, 
and clinical pharmacist. Prior to this initiative, medication 
monitoring had not been systematically evaluated through 
database management.  
 
Database Development 
Creation of a medication management database for 
psychotropic monitoring was undertaken. The literature was 
reviewed for evidence-based guidelines for monitoring of the 
following categories: antipsychotics, antidepressants, and 
mood stabilizers. Search terms included antidepressant, 
antipsychotic, bipolar disorder, guidelines, medication 
management, mood stabilizer, schizoaffective, and 
schizophrenia. Databases used for searches were EBSCOhost, 
Medline, PsycINfo, and PubMed for the period 1968 to March 
2012. After the literature was obtained, at least two of the 
authors reviewed each article.  
 
This project was reviewed and approved by the institutional 
review board. Anonymity was maintained throughout the 
project. Inclusion of information into the IMPACT database 
was protected in accordance with university policies and 
procedures. Individual monitoring information was 
categorical and for analysis only. No protected health 
information was involved with aggregate reporting. 
Descriptive statistics were used.  
 
Monitoring Needs and Results 
Medication regimens for 68 IMPACT members qualified for 
review. Fourteen medications, including products available as 
both long-acting injection (LAI) and oral formulations, were 
identified for inclusion in the database for monitoring. A total 
of 111 medications, including four LAIs, were found to be 
used on a monthly basis. Each IMPACT member had more 
than one medication entered into the medication 
management database.  
 
Once the database was developed and all medication 
regimens entered, the medical director reviewed the charts 
to determine if additional monitoring was needed on a case-
by-case basis. Additional changes were made. Orders for 
fasting blood glucose were discontinued (n=2, 100%) and 
changed [to ‘attempt fasting status’ and ‘obtain glycosylated 
hemoglobin (A1c)] and scheduled for every 6 months. Annual 
lipid panels were changed to every 6 months.  
 
Discussion 
PACT teams are not new. The first initiatives were reported in 
the 1970s.
1
 The focus at that time was housing and substance 
abuse treatment.
8
 The role of the pharmacist providing 
clinical services to chronic psychiatric outpatients was 
reported in 1978.
9
 In addition to that initial work, the role of 
the pharmacist in mental health settings has been recognized 
and the advantages evaluated.
10
 One example was the 
development of a psychiatric pharmacy clinic for indigent 
patients. In this initiative, an underserved population of clinic 
patients with mental health concerns was referred to the 
psychiatric pharmacist. Outcomes included a greater than 
90% acceptance rate of pharmacist-initiated 
recommendations and cost savings.
11
  
 
Why Scheduled Monitoring Is Needed 
Persons with SMIs face a number of challenges. These include 
(but are not limited to) comorbidities of substance use 
disorders, homelessness, chronic health conditions, and 
metabolic and/or endocrine disorders secondary to 
medication use. The IMPACT program includes scheduled 
monitoring for movement disorders and medication reviews. 
Specific medications are monitored as identified in  
Appendix 2.  
 
In addition to medication-related adverse effects the patient 
may experience and may or may not report, monitoring for 
endocrine and metabolic changes has the potential to avoid 
long-term medication-induced consequences. Life expectancy 
for persons with a diagnosis of schizophrenia has been 
correlated with increased mortality equating with a lifespan 
up to 25 years shorter.
2
 In a meta-analysis involving 152 
mortality studies, the risk of premature death in persons with 
a diagnosis of schizophrenia was twice as great when 
compared to persons in the general population. 
Cardiovascular diseases were found to be the leading 
mortality event. Risk factors included obesity, hypertension, 
dyslipidemia, and elevated glucose levels. The authors 
recognized the predisposition to adverse metabolic 
consequences did include contributing factors amenable to 
change, such as dietary choices and exercise. Factors 
associated with significant antipsychotic-induced weight gain 
were a lower body mass index at pharmacotherapy initiation, 
choice of agent, duration of use, and age (younger vs. older 
patients). The choice of first or second generation agent had 
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an effect on lipid changes. Clozapine, olanzapine, and 
quetiapine were associated with more hyperlipidemia. 
Haloperidol was less associated with lipid elevations than 
chlorpromazine for first generation agents. Consistent with 
recommendations for the general population, the author 
recommended regular exercise, weight management (or 
weight loss), blood pressure control, and smoking cessation 
as management strategies. Medication monitoring 
recommendations included baseline glucose evaluations with 
monitoring no less than every 6 months.  
 
The presence of diabetes and schizophrenia may be 
associated with poorer glucose control compared to persons 
not dually diagnosed with diabetes and a SMI (schizophrenia 
specifically) although results differed with the study 
populations.
12,13
 A number of strategies were proposed for 
prolactin elevations, but specific monitoring guidelines were 
not provided.
5
 The medication monitoring form developed 
for use in the IMPACT program includes general patient 
information (weight or body mass index, waist circumference, 
and vital signs), a lipid panel, laboratory work specific for 
mood stabilizers (lithium, divalproex, and carbamazepine), 
and an assessment for movement disorders (Abnormal 
Involuntary Movement Scale or AIMS).  
 
One of the anticipated outcomes with the creation of the 
database was coordination of care with the primary care 
provider (PCP). Prior to the database, the comprehensive 
metabolic panel and complete blood count were ordered by 
the PCP. Records and appointments with the PCP were not 
always available to the IMPACT team. Some providers have 
electronic data management; others do not. A specific 
example of why coordination of care and systematic lab 
review is needed is provided.  
 
Case Example 
Psychiatric medication-related monitoring was ordered and 
managed by the psychiatrist with correspondence of the 
results transmitted to the PCP via an electronic medical 
record (EMR). Posted results from outside providers, like labs 
or diagnostic tests, could take up to 30 days to be entered 
into the system. Lab results were not readily available for this 
patient. This resulted in the need for a medical hospitalization 
for a 34-year old IMPACT member (white male) with medical 
comorbidities of high density lipoproteins (HDL) less than 40 
mg/dL (desired range for men: > 40 mg/dL), 
hypertriglyceridemia, tachycardia, and obesity. Psychiatric 
diagnoses of schizophrenia, paranoid type, anxiety not 
otherwise specified, and nicotine dependence were well-
controlled with a regimen of clozapine 800 mg, divalproex 
extended release 2000 mg, zolpidem 10 mg, and propranolol 
extended release 160 mg, all administered at bedtime. 
Medication prescribed by the PCP had been discontinued as 
the member had not been seen by the provider for 
approximately 18 months. This information was not provided 
to the IMPACT team. The member received home-based 
services from the team three times weekly. Four days prior to 
hospitalization the member was seen by the IMPACT nurse. 
He complained of flu-like symptoms and flank pain. He 
declined any interventions, including medical assistance. One 
day prior to admission, he was again seen by the nurse. The 
member declined to contact his PCP or schedule a visit. The 
following day the member was admitted for medical reasons. 
A diagnosis of pancreatitis was made at that time. Diabetes 
was diagnosed during this inpatient admission. Had a system 
for scheduled, systematic medication monitoring and 
coordination of care been in place, we theorize that 
hospitalization may have been avoided with better 
communication between healthcare providers.  
 
Monitoring as a Quality Assurance Activity 
While pharmacy-based interventions in medication 
adherence
14
 and clinical pharmacist interventions with a 
PACT team
15
 have been previously reported, programs with 
regular pharmacist involvement in longitudinal antipsychotic 
monitoring were not found. The goals of the monitoring 
program were to help ensure members receive the most 
effective care, to minimize potential medication-related 
adverse effects and to improve coordination of care between 
medical and psychiatric providers. It is anticipated this 
monitoring program will address these goals.  
 
In addition, the monitoring program was incorporated into 
the continuous quality assurance activities used by the 
IMPACT team and represents an ongoing activity. Members 
are scheduled for clinic either twice a month or monthly. Lab 
results are reviewed and discussed at least monthly during 
clinic appointments. The program will be evaluated annually 
and adjusted as needed to meet the needs of the IMPACT 
members.  
 
Individual member monitoring also was incorporated into the 
monthly medication reviews done by the psychiatric resident 
and reviewed by the psychiatrist and clinical pharmacist. The 
form and compete information have been added to the 
service-specific university-maintained secure drive.  
(Appendix 2)  
 
Challenges and Future Directions 
Ongoing challenges for coordination of care for a 
psychiatrically and medically complex population include 
ensuring medication regimens are reviewed and the reviewer 
has access to the most current information. Developing the 
database and including this information on a shared service-
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specific drive were implemented to facilitate integration. 
Programs interested in adding database monitoring 
development need to provide resources for this task. We 
found this process involved significant time for development 
and revisions. Resources available for development included 
access to an electronic medical record (EMR). This also was 
one of the limitations: access to an EMR. Identifying the 
group of service providers that utilize an EMR and those that 
do not and addressing coordination of care with the needs of 
each provider group will help ensure better medication 
management between medical and psychiatric areas of 
concern.  
 
Because the medication monitoring database has been in 
existence for only a short time, long-term gains cannot be 
reported at this time. A more comprehensive medication 
management project is in development to specifically identify 
pharmacist-managed interventions and how these 
interventions benefitted the IMPACT member, service, and 
program. Specific areas include clearly identifying 
interventions and outcomes. It is not known at this time if 
cost savings will be included as a project outcome. In 
addition, implementation methods are in development to 
address the secondary goal of improving coordination of care 
with identification of resources for this phase. Following 
implementation of this component, it is anticipated one year 
of data collection will help identify and focus what additional 
oversight is needed in this area. Inclusion of primary 
medication concerns will be evaluated for inclusion.  
 
Conclusions 
Multiple medications to treat patients with severe mental 
illness are used on a regular basis for members enrolled in 
the IMPACT program to address their psychiatric needs. 
Development of a database to facilitate psychiatrically-
indicated medication monitoring, help ensure members 
enrolled in the IMPACT program, and improve coordination 
of care between PCPs and the IMPACT team was undertaken. 
Additional phases to address these goals will be needed. 
Integration into scheduled monitoring in a readily available 
format will be reviewed to ensure the information is updated 
and follow-up initiated.  
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Appendix 1 
Admission Criteria for the IMPACT Program 
 
Primary Criterion:  
 Adults with a primary diagnosis of schizophrenia or other psychotic disorders limited to schizoaffective disorder or bipolar 
disorder with psychotic features.  
 
Additional criteria of at least four of the following risk factors:  
 Admission and/or length-of-stay (LOS) parameters for psychiatrically-related admissions: four hospitalizations OR a LOS greater 
than 30 days total time in the past 12 months;  
 Severe symptoms that are persistent or recurrent and are affective, psychotic, or suicidal;  
 A comorbid substance abuse disorder in existence more than 6 months;  
 Either high risk for or involvement in the criminal justice system in the past 12 months;  
 If not homeless, there is an imminent risk for homelessness OR housing is unsafe or substandard; and/or  
 Functional status has been clinically evaluated such that supported housing as a residential choice is possible if intensive 
services are provided OR supported housing is required if more intensive services are not available.  
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Appendix 2 
IMPACT Antipsychotic Monitoring 
Monitor Needed/Date Baseline 12 Weeks Monthly Every 6 months Annually 
CMP      
Weight/BMI      
Waist circumference      
BP      
Fasting BG/A1c      
Fasting Lipid Profile      
CMP = comprehensive metabolic panel; BMI = body mass index; BP = blood pressure; BG = blood glucose 
 
Current BMI: _________________ Ht: __________________ Weight: _____________________ 
Fasting Lipid Panel 
Date of most recent labs: ________________________________________________________ 
Results: Cholesterol: _______________________________________________________ 
Triglycerides: ______________________________________________________ 
LDL: _____________________________________________________________ 
HDL: _____________________________________________________________ 
Ordered: __________________________________________________________ 
LDL = low-density lipoprotein; HDL = high-density lipoprotein 
Comments: ______________________________________________________________ 
 
Fasting Blood Glucose (FBG) or Glycosylated hemoglobin (A1c) 
Date of most recent lab(s): ________________________________________________________ 
Results: FBG: _____________________________________________________________ 
A1c: _____________________________________________________________ 
Ordered: __________________________________________________________ 
Comments: ______________________________________________________________ 
 
Lithium (Li): every 6 months 
Date of most recent lab(s): ________________________________________________________ 
Results: BMP: _______________________________________________________ 
TSH: ________________________________________________________ 
Li Level: _____________________________________________________ 
Ordered: _____________________________________________________ 
BMP = basic metabolic panel; TSH = thyroid stimulating hormone 
Comments: ______________________________________________________________ 
 
Valproic Acid (VPA): every 6 months 
Date of most recent lab(s): __________________________________________________ 
Results: CMP: _______________________________________________________ 
CBC: ________________________________________________________ 
VPA Level: ____________________________________________________ 
Ordered: ____________________________________________________ 
CMP = comprehensive metabolic panel; CBC = complete blood count 
Comments: ______________________________________________________________ 
 
Carbamazepine (CBZ): every 6 months 
Date of most recent lab(s): ________________________________________________________ 
Results: CMP: _______________________________________________________ 
CBC: ________________________________________________________ 
CBZ Level: ____________________________________________________ 
Ordered: ____________________________________________________ 
Comments: ______________________________________________________________ 
 
Abnormal Involuntary Movement Scale (AIMS): Score/date: _____________/_______________ 
 
